In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
Latest article
Fin-ished, for now: Aqua Cultured Foods shutters as funding dries up
In Chicago, a fermentation startup converting cellulose into seafood alternatives has wound down operations after failing to raise funds necessary to reach commercialization.
Established...
Mercedes unveils vegan-interior SUV at CES
In Nevada, Mercedes-Benz has showcased a new, vegan-interior GLC electronic SUV at the recent CES technology trade show in Las Vegas.
Vegan materials were...
Futerro files permits for French PLA site
In France, biobased chemicals maker Futerro has requested the relevant permits for its planned lactic acid and polylactic acid plant in France.
The plant, which...